News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2019

June

Media Release / Jun 12, 2019

Long-term survival data for metastatic melanoma patients treated with Tafinlar® + Mekinist® published in NEJM and presented at ASCO

Read More

May

Media Release / May 03, 2019

Novartis Canada celebrates annual Community Partnership Day across Quebec

Read More
2018

December

Media Release / Dec 03, 2018

Novartis’ CGRP inhibitor Aimovig® (erenumab) now available in Canada for the prevention of migraine

Read More

November

Media Release / Nov 21, 2018

Novartis heart failure treatment Entresto® is awarded prestigious Prix Galien Canada Innovative Product Award

Read More
Media Release / Nov 13, 2018

Inclusion of data on treatment discontinuation in the Tasigna® product monograph approved by Health Canada for CML patients who achieve a sustained molecular response

Read More
Media Release / Nov 01, 2018

Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma

Read More

September

Media Release / Sep 27, 2018

‘My Heart Failure Hero’ project launches on World Heart Day

Read More
Media Release / Sep 13, 2018

Novartis employees complete 14th annual 600-km Ride for Life raising funds for Quebec Breast Cancer Foundation

Read More
Media Release / Sep 06, 2018

Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah™ (tisagenlecleucel)

Read More

August

Media Release / Aug 01, 2018

AimovigTM (erenumab), a novel treatment developed specifically for migraine prevention receives Health Canada approval

Read More

Pages